RoosterVial-hBM-20M-CCModel cGMP - MSC-CC040 -Xeno-Free Human Bone Marrow-Derived MSCs

SHARE

cGMP xeno-free human bone marrow-derived MSCs to support allogenic therapeutic cell manufacturing. Using a comprehensive and qualified supply chain of our high volume, well-characterized, and standardized WCBs (working cell banks) for large scale cell manufacturing – you’re now able to bypass major steps in cGMP manufacturing. With a rapid 2D process and path to Phase 1 – using 20 x 10-layer vessels, CliniControl™ hMSCs and media get you to the clinic faster, and then scale with your clinical progression to meet your lot size requirements.

Most popular related searches

A high quality allogeneic, off-the-shelf WCB for therapeutic cell manufacturing, CliniControl™ (CC) bone marrow-derived hMSCs are manufactured with methods and controls that conform with current Good Manufacturing Practices (cGMP) and are supported for use as a manufacturing starting material by a Master File on file with the FDA. Time spent on investigational new drug (IND) submissions is significantly reduced by facilitating CMC documentation.

To further accelerate your translational research, this clinically-relevant WCB can be tested in development prior to cGMP manufacturing.

Intended Use:  For Further Manufacturing Use Only. Not intended for diagnostic use or for direct human or veterinary therapeutic use.

  • 20M cryopreserved XF cells per vial – manufactured under cGMP
  • Off-the-shelf WCB – bypasses the need of qualifying and releasing an MCB (master cell bank) and WCBs
  • Industry-leading functional characterization
  • Tissue of Origin: Healthy human bone marrow
  • Supported by a US FDA Type II Master File – available for cross reference
  • RoosterVial™-hBM-20M-CC contributes to an economical cost of goods and dramatically impacts efficiencies in path to commercialization
  • CliniControl™ products achieve clinically-relevant lot sizes (of consistent PDL) in days, not weeks
  • Use with CliniControl™ bioprocess medium for an anticipated lot size yield of more than 3B hMSCs per our process recommendations
  • Seamless 2D (batch) to 3D (fed-batch) culture
  • Multiple donors available
  • Cryopreserved using a controlled and fully XF preservation process

*Media needs will be dependent on customer’s process.